HFV 1017

Drug Profile

HFV 1017

Alternative Names: HFV 1017C

Latest Information Update: 17 Jan 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Fine Chemical
  • Class Antithrombotics
  • Mechanism of Action Platelet aggregation inhibitors; Type 1 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Thrombosis

Most Recent Events

  • 17 Jan 2001 Discontinued-Preclinical for Thrombosis in Japan (Unknown route)
  • 29 Jan 1998 Two studies have been added to the Thromboses pharmacodynamics section ,
  • 06 Nov 1996 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top